Do analysts recommend RGC or ARDX?

Ardelyx has a consensus target price of $15.73, suggesting a potential upside of 154.49%. Given Ardelyx's stronger consensus rating and higher probable upside, analysts plainly believe Ardelyx is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ardelyx 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.91

Which has preferable earnings & valuation, RGC or ARDX?

Regencell Bioscience has higher earnings, but lower revenue than Ardelyx. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Ardelyx $407.32M 3.75 -$61.60M -$0.23 N/A

Does the media prefer RGC or ARDX?

In the previous week, Regencell Bioscience had 20 more articles in the media than Ardelyx. MarketBeat recorded 22 mentions for Regencell Bioscience and 2 mentions for Ardelyx. Ardelyx's average media sentiment score of 1.04 beat Regencell Bioscience's score of 0.03 indicating that Ardelyx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 20 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Ardelyx 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ARDX or COGT?

In the previous week, Ardelyx and Ardelyx both had 2 articles in the media. Ardelyx's average media sentiment score of 1.04 beat Cogent Biosciences' score of 0.36 indicating that Ardelyx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ardelyx 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cogent Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, ARDX or BLTE?

Ardelyx has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ardelyx $407.32M 3.75 -$61.60M -$0.23 N/A Belite Bio N/A N/A -$77.61M -$2.53 N/A

Is ARDX or BLTE more profitable?

Belite Bio has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Belite Bio's return on equity of -13.14% beat Ardelyx's return on equity. Company Net Margins Return on Equity Return on Assets Ardelyx -13.58% -38.11% -11.85% Belite Bio N/A -13.14% -12.88%

Does the media favor ARDX or BLTE?

In the previous week, Belite Bio had 3 more articles in the media than Ardelyx. MarketBeat recorded 5 mentions for Belite Bio and 2 mentions for Ardelyx. Ardelyx's average media sentiment score of 1.04 beat Belite Bio's score of -0.54 indicating that Ardelyx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ardelyx 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Belite Bio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Which has higher earnings and valuation, ARDX or SRRK?

Ardelyx has higher revenue and earnings than Scholar Rock. Ardelyx is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ardelyx $407.32M 3.75 -$61.60M -$0.23 N/A Scholar Rock N/A N/A -$377.94M -$3.59 N/A

Is ARDX or SRRK more profitable?

Scholar Rock has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Ardelyx's return on equity of -38.11% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Ardelyx -13.58% -38.11% -11.85% Scholar Rock N/A -163.52% -96.67%

Does the media favor ARDX or SRRK?

In the previous week, Scholar Rock had 3 more articles in the media than Ardelyx. MarketBeat recorded 5 mentions for Scholar Rock and 2 mentions for Ardelyx. Scholar Rock's average media sentiment score of 1.57 beat Ardelyx's score of 1.04 indicating that Scholar Rock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ardelyx 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to APGE or ARDX?

In the previous week, Apogee Therapeutics had 32 more articles in the media than Ardelyx. MarketBeat recorded 34 mentions for Apogee Therapeutics and 2 mentions for Ardelyx. Ardelyx's average media sentiment score of 1.04 beat Apogee Therapeutics' score of 0.61 indicating that Ardelyx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 12 Very Positive mention(s) 3 Positive mention(s) 14 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Ardelyx 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ardelyx (ARDX) Competitors

$6.18 -0.19 (-2.98%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$6.22 +0.04 (+0.73%)

As of 06/23/2026 07:57 PM Eastern

Compare

ARDX vs. RGC, COGT, BLTE, SRRK, and APGE

Should you buy Ardelyx stock or one of its competitors? MarketBeat compares Ardelyx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ardelyx include Regencell Bioscience (RGC), Cogent Biosciences (COGT), Belite Bio (BLTE), Scholar Rock (SRRK), and Apogee Therapeutics (APGE). These companies are all part of the "pharmaceutical products" industry.

How does Ardelyx compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Ardelyx (NASDAQ:ARDX) are both pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

Ardelyx has a consensus target price of $15.73, suggesting a potential upside of 154.49%. Given Ardelyx's stronger consensus rating and higher probable upside, analysts plainly believe Ardelyx is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

In the previous week, Regencell Bioscience had 20 more articles in the media than Ardelyx. MarketBeat recorded 22 mentions for Regencell Bioscience and 2 mentions for Ardelyx. Ardelyx's average media sentiment score of 1.04 beat Regencell Bioscience's score of 0.03 indicating that Ardelyx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	20 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Ardelyx	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Regencell Bioscience has higher earnings, but lower revenue than Ardelyx.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Ardelyx	$407.32M	3.75	-$61.60M	-$0.23	N/A

Regencell Bioscience has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Regencell Bioscience's return on equity of 0.00% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Ardelyx	-13.58%	-38.11%	-11.85%

0.1% of Regencell Bioscience shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 5.3% of Ardelyx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Regencell Bioscience has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market. Comparatively, Ardelyx has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market.

Summary

Ardelyx beats Regencell Bioscience on 8 of the 14 factors compared between the two stocks.

How does Ardelyx compare to Cogent Biosciences?

Ardelyx (NASDAQ:ARDX) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

Ardelyx has higher revenue and earnings than Cogent Biosciences. Ardelyx is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$407.32M	3.75	-$61.60M	-$0.23	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

Ardelyx has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market.

Ardelyx currently has a consensus target price of $15.73, suggesting a potential upside of 154.49%. Cogent Biosciences has a consensus target price of $43.73, suggesting a potential upside of 20.43%. Given Ardelyx's stronger consensus rating and higher probable upside, equities research analysts clearly believe Ardelyx is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

In the previous week, Ardelyx and Ardelyx both had 2 articles in the media. Ardelyx's average media sentiment score of 1.04 beat Cogent Biosciences' score of 0.36 indicating that Ardelyx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ardelyx	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cogent Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

58.9% of Ardelyx shares are held by institutional investors. 5.3% of Ardelyx shares are held by insiders. Comparatively, 6.6% of Cogent Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Cogent Biosciences has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Ardelyx's return on equity of -38.11% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-13.58%	-38.11%	-11.85%
Cogent Biosciences	N/A	-104.27%	-54.64%

Summary

Ardelyx beats Cogent Biosciences on 10 of the 14 factors compared between the two stocks.

How does Ardelyx compare to Belite Bio?

Ardelyx (NASDAQ:ARDX) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

58.9% of Ardelyx shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 5.3% of Ardelyx shares are owned by insiders. Comparatively, 13.3% of Belite Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Ardelyx presently has a consensus price target of $15.73, suggesting a potential upside of 154.49%. Belite Bio has a consensus price target of $203.00, suggesting a potential upside of 39.91%. Given Ardelyx's stronger consensus rating and higher possible upside, equities research analysts clearly believe Ardelyx is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Belite Bio had 3 more articles in the media than Ardelyx. MarketBeat recorded 5 mentions for Belite Bio and 2 mentions for Ardelyx. Ardelyx's average media sentiment score of 1.04 beat Belite Bio's score of -0.54 indicating that Ardelyx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ardelyx	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Belite Bio	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Ardelyx has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Comparatively, Belite Bio has a beta of -1.24, suggesting that its share price is 224% less volatile than the broader market.

Belite Bio has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Belite Bio's return on equity of -13.14% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-13.58%	-38.11%	-11.85%
Belite Bio	N/A	-13.14%	-12.88%

Ardelyx has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$407.32M	3.75	-$61.60M	-$0.23	N/A
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A

Summary

Ardelyx beats Belite Bio on 12 of the 16 factors compared between the two stocks.

How does Ardelyx compare to Scholar Rock?

Ardelyx (NASDAQ:ARDX) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Ardelyx presently has a consensus price target of $15.73, suggesting a potential upside of 154.49%. Scholar Rock has a consensus price target of $56.00, suggesting a potential upside of 9.23%. Given Ardelyx's higher probable upside, research analysts plainly believe Ardelyx is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12

58.9% of Ardelyx shares are owned by institutional investors. Comparatively, 91.1% of Scholar Rock shares are owned by institutional investors. 5.3% of Ardelyx shares are owned by insiders. Comparatively, 13.3% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Ardelyx has higher revenue and earnings than Scholar Rock. Ardelyx is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$407.32M	3.75	-$61.60M	-$0.23	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A

In the previous week, Scholar Rock had 3 more articles in the media than Ardelyx. MarketBeat recorded 5 mentions for Scholar Rock and 2 mentions for Ardelyx. Scholar Rock's average media sentiment score of 1.57 beat Ardelyx's score of 1.04 indicating that Scholar Rock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ardelyx	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Ardelyx has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market.

Scholar Rock has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Ardelyx's return on equity of -38.11% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-13.58%	-38.11%	-11.85%
Scholar Rock	N/A	-163.52%	-96.67%

Summary

Scholar Rock beats Ardelyx on 10 of the 16 factors compared between the two stocks.

How does Ardelyx compare to Apogee Therapeutics?

Apogee Therapeutics (NASDAQ:APGE) and Ardelyx (NASDAQ:ARDX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.

Ardelyx has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.33	N/A
Ardelyx	$407.32M	3.75	-$61.60M	-$0.23	N/A

79.0% of Apogee Therapeutics shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 24.3% of Apogee Therapeutics shares are owned by insiders. Comparatively, 5.3% of Ardelyx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Apogee Therapeutics has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Apogee Therapeutics' return on equity of -32.64% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-32.64%	-31.25%
Ardelyx	-13.58%	-38.11%	-11.85%

Apogee Therapeutics currently has a consensus target price of $119.67, indicating a potential downside of 9.94%. Ardelyx has a consensus target price of $15.73, indicating a potential upside of 154.49%. Given Ardelyx's stronger consensus rating and higher probable upside, analysts clearly believe Ardelyx is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	13 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.30
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

Apogee Therapeutics has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market. Comparatively, Ardelyx has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market.

In the previous week, Apogee Therapeutics had 32 more articles in the media than Ardelyx. MarketBeat recorded 34 mentions for Apogee Therapeutics and 2 mentions for Ardelyx. Ardelyx's average media sentiment score of 1.04 beat Apogee Therapeutics' score of 0.61 indicating that Ardelyx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apogee Therapeutics	12 Very Positive mention(s)	3 Positive mention(s)	14 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Ardelyx	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ardelyx beats Apogee Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Ardelyx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARDX vs. The Competition

Export

Metric	Ardelyx	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.57B	$2.97B	$6.45B	$12.39B
Dividend Yield	N/A	1.80%	2.69%	5.83%
P/E Ratio	-26.87	18.43	24.92	23.98
Price / Sales	3.75	327.41	528.23	109.07
Price / Cash	N/A	56.31	44.82	54.51
Price / Book	8.96	4.11	10.79	6.50
Net Income	-$61.60M	$64.45M	$3.56B	$336.88M
7 Day Performance	5.82%	1.41%	1.00%	-0.14%
1 Month Performance	1.15%	1.04%	0.42%	0.77%
1 Year Performance	67.93%	23.88%	29.70%	28.49%

Ardelyx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARDX Ardelyx	2.6476 of 5 stars	$6.18 -3.0%	$15.73 +154.5%	+70.2%	$1.57B	$407.32M	N/A	90
RGC Regencell Bioscience	0.3967 of 5 stars	$10.51 -12.5%	N/A	-53.2%	$5.94B	N/A	N/A	10	Trending News High Trading Volume
COGT Cogent Biosciences	2.049 of 5 stars	$35.84 +3.8%	$43.73 +22.0%	+400.1%	$5.90B	N/A	N/A	80
BLTE Belite Bio	3.0283 of 5 stars	$147.07 +0.7%	$203.00 +38.0%	+135.9%	$5.86B	N/A	N/A	10	Insider Trade
SRRK Scholar Rock	2.1061 of 5 stars	$49.19 +3.9%	$56.00 +13.8%	+54.1%	$5.67B	N/A	N/A	140	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARDX) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ardelyx (ARDX) Competitors

ARDX vs. RGC, COGT, BLTE, SRRK, and APGE

How does Ardelyx compare to Regencell Bioscience?

Summary

How does Ardelyx compare to Cogent Biosciences?

Summary

How does Ardelyx compare to Belite Bio?

Summary

How does Ardelyx compare to Scholar Rock?

Summary

How does Ardelyx compare to Apogee Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARDX vs. The Competition

Ardelyx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ardelyx (ARDX) Competitors

ARDX vs. RGC, COGT, BLTE, SRRK, and APGE

How does Ardelyx compare to Regencell Bioscience?

Do analysts recommend RGC or ARDX?

Does the media prefer RGC or ARDX?

Which has preferable earnings & valuation, RGC or ARDX?

Is RGC or ARDX more profitable?

Do institutionals & insiders have more ownership in RGC or ARDX?

Which has more volatility and risk, RGC or ARDX?

Summary

How does Ardelyx compare to Cogent Biosciences?

Which has preferable valuation and earnings, ARDX or COGT?

Which has more volatility & risk, ARDX or COGT?

Do analysts recommend ARDX or COGT?

Does the media refer more to ARDX or COGT?

Do institutionals and insiders hold more shares of ARDX or COGT?

Is ARDX or COGT more profitable?

Summary

How does Ardelyx compare to Belite Bio?

Do institutionals and insiders have more ownership in ARDX or BLTE?

Do analysts prefer ARDX or BLTE?

Does the media favor ARDX or BLTE?

Which has more risk & volatility, ARDX or BLTE?

Is ARDX or BLTE more profitable?

Which has stronger earnings & valuation, ARDX or BLTE?

Summary

How does Ardelyx compare to Scholar Rock?

Do analysts prefer ARDX or SRRK?

Do insiders & institutionals have more ownership in ARDX or SRRK?

Which has higher earnings and valuation, ARDX or SRRK?

Does the media favor ARDX or SRRK?

Which has more volatility and risk, ARDX or SRRK?

Is ARDX or SRRK more profitable?

Summary

How does Ardelyx compare to Apogee Therapeutics?

Which has stronger earnings & valuation, APGE or ARDX?

Do insiders and institutionals believe in APGE or ARDX?

Is APGE or ARDX more profitable?

Do analysts recommend APGE or ARDX?

Which has more volatility and risk, APGE or ARDX?

Does the media refer more to APGE or ARDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARDX vs. The Competition

Ardelyx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools